
A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, avoiding exposure to the rest of the body.
This supports continuing the trial, said Dr. John H. Sampson of Duke University Medical Center’s Department of Neurosurgery.
Sampson presented a poster, “Real time, image guided high flow CED in recurrent glioblastoma (rGBM); initial experience from phase 2 study of a targeted immunotherapy, MDNA55 (cpIL-4PE),” at the 2017 Congress of Neurological Surgeons.
“Drug delivery to the brain has been a challenge and these initial data are a significant advance in our attempt to safely and efficiently deliver our targeted cancer immunotherapy agent MDNA55,” Dr. Martin Bexon, Medicenna’s head of clinical development, said in a press release. “Our initial experience has shown that it is possible to accurately deliver the volumes at high flow rates necessary for distribution of MDNA55 in and around the tumor. This was achieved with a reassuring safety profile, such that our safety committee recommended continuation of the study.”
Source: Immuno-Oncology News







